title: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
abstract: OBJECTIVE
  To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer.
  
  
  METHODS
  A total of 248 patients with advanced measurable colorectal cancer previously unexposed to chemotherapy were randomly assigned to treatment with either FU (400 mg/m2/d by intravenous [I.V.] infusion for 2 hours) and racemic LV (100 mg/m2/d by I.V. bolus injection) given for 5 consecutive days, or the combination of FU and the pure l-isomer of LV using the same dose schedule. In both treatment arms, courses were administered every 28 days if toxicity allowed for a total of 6 months, unless evidence of tumor progression was documented earlier.
  
  
  RESULTS
  There were no significant differences between the FU/racemic LV and the FU/l-LV arm in the overall response rate (25% v 32%), duration of response (7.2 v 8.0 months), median time to progression or death (6.25 v 8.0 months), or median overall survival time (14.5 v 15.0 months). Except for minor myeloid toxic effects associated with FU/l-LV, there was also no significant difference in terms of adverse reactions. Gastrointestinal symptoms, specifically mucasitis and diarrhea, were less frequent and less severe in both treatment arms compared with other trials with FU/racemic LV reported in the literature, which might be because of the prolonged administration of FU used in both arms.
  
  
  CONCLUSIONS
  The combination of FU/l-LV produced response rates, response durations, and survival times similar to those with FU/d,l-LV. Biochemical modulation of FU by either pure l-LV or racemic LV thus appears to result in equivalent clinical efficacy.
authors.affiliation: Department of Internal Medicine I/Division of Oncology, Vienna University Medical School, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Scheithauer
authors.forename: G
authors.initials: G
authors.lastname: Kornek
authors.forename: A
authors.initials: A
authors.lastname: Marczell
authors.forename: G
authors.initials: G
authors.lastname: Salem
authors.forename: J
authors.initials: J
authors.lastname: Karner
authors.forename: E
authors.initials: E
authors.lastname: Kovats
authors.forename: D
authors.initials: D
authors.lastname: Burger
authors.forename: R
authors.initials: R
authors.lastname: Greiner
authors.forename: J
authors.initials: J
authors.lastname: Pidlich
authors.forename: B
authors.initials: B
authors.lastname: Schneeweiss
authors.forename: M
authors.initials: M
authors.lastname: Raderer
authors.forename: H
authors.initials: H
authors.lastname: Rosen
authors.forename: D
authors.initials: D
authors.lastname: Depisch
mesh_terms: D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000931:Antidotes / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000737:chemistry / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013237:Stereoisomerism; D016019:Survival Analysis
chemical_list: D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil